Weight loss and hormone pill tested for fertility-sparing cancer treatment – but trial stopped early

NCT ID NCT05316467

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether combining weight management (diet and exercise guidance) with a daily hormone pill (megestrol acetate) could help obese patients with early-stage endometrial cancer who want to preserve their fertility. The goal was to see if the cancer would completely respond within 28 weeks. However, the trial was terminated early and only enrolled 8 people, so we cannot draw strong conclusions from it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Megestrol acetate (a hormone drug) plus intensive lifestyle intervention (diet and exercise guidance)
What this could lead to
If it had succeeded, this approach could have offered a way to control early endometrial cancer while preserving fertility in obese patients.
What could go wrong
The trial was terminated early with only 8 participants, so results are very limited. It is unclear if the combination works better than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY-STAGE ENDOMETRIOID CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Obstetrics and Gynecology Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.